Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease

Abstract

IMPORTANCE The amyloid/tau/neurodegeneration (A/T/N) framework uses cerebrospinal fluid (CSF) levels of total tau (tTau) as a marker of neurodegeneration and CSF levels of phosphorylated tau 181 (pTau181) as a marker of tau tangles. However, it is unclear whether CSF levels of tTau and pTau181 have similar or different trajectories over the course of Alzheimer disease. OBJECTIVES To examine the rates of change in CSF levels of tTau and pTau181 across the Alzheimer disease course and how the rates of change are associated with brain atrophy as measured by magnetic resonance imaging. DESIGN, SETTING, AND PARTICIPANTS This cohort study was set in tertiary research clinics. Each participant was a member of a pedigree with a known mutation for dominantly inherited Alzheimer disease. Participants were divided into 3 groups on the basis of the presence of a mutation and their Clinical Dementia Rating score. Data analysis was performed in June 2019. MAIN OUTCOMES AND MEASURES Rates of change of CSF tTau and pTau181 levels and their association with the rate of change of brain volume. RESULTS Data from 465 participants (283 mutation carriers and 182 noncarriers) were analyzed. The mean (SD) age of the cohort was 37.8 (11.3) years, and 262 (56.3%) were women. The mean (SD) follow-up duration was 2.7 (1.5) years. Two or more longitudinal CSF and magnetic resonance imaging assessments were available for 160 and 247 participants, respectively. Sixty-five percent of mutation carriers (183) did not have symptoms at baseline (Clinical Dementia Rating score, 0). For mutation carriers, the annual rates of change for CSF tTau and pTau181 became significantly different from 0 approximately 10 years before the estimated year of onset (mean [SE] rates of change, 5.5 [2.8] for tTau [P = .05] and 0.7 [0.3] for pTau 181 [P = .04]) and 15 years before onset (mean [SE] rates of change, 5.4 [3.9] for tTau [P = .17] and 1.1 [0.5] for pTau181 [P = .03]), respectively. The rate of change of pTau181 was positive and increased at the early stages of the disease, showing a positive rate of change starting at 15 estimated years before onset until 5 estimated years before onset (mean [SE], 0.4 [0.3]), followed by a positive but decreasing rate of change at year 0 (mean [SE], 0.1 [0.3]) and then negative rates of change at 5 years (mean [SE], −0.3 [0.4]) and 10 years (mean [SE], −0.6 [0.6]) after symptom onset. In individuals without symptoms (Clinical Dementia Rating score, 0), the rates of change of CSF tTau and pTau181 were negatively associated with brain atrophy (high rates of change in CSF measures were associated with low rates of change in brain volume in asymptomatic stages). After symptom onset (Clinical Dementia Rating score, >0), an increased rate of brain atrophy was not associated with rates of change of levels of both CSF tTau and pTau181. (continued) Key Points Question How do different proposed measurements of tau brain pathologic abnormalities (ie, levels of phosphorylated tau 181 in the cerebrospinal fluid [CSF]) and neurodegenera...

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease

“…The current findings between plasma pTau181 and brain atrophy corroborate previous research on CSF and plasma pTau181 [ 6 , 28 ]. Higher levels of phosphorylated tau predicted neurodegeneration in the medial temporal and periventricular WM among other regions in aging and AD [ 28 , 29 ]. In CI individuals, plasma pTau181 was correlated with degeneration of GM in the precuneus and temporal lobes [ 6 ].…”

Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease

“…CSF and blood-based biomarkers reflect properties of the brain and body at the time of collection. Prior work suggested that CSF biomarkers of neuronal injury decline at symptomatic stages of AD ( Llibre-Guerra et al, 2019 ; Sutphen et al, 2018 ), which could lead to a mismatch between biofluid and imaging markers in later stages of disease. Further work is needed to test whether the relationship between imaging and NfL measures changes at more advanced stages of neurodegenerative conditions.…”

Differential Circulating Levels of Naturally Occurring Antibody to α-Synuclein in Parkinson’s Disease Dementia, Alzheimer’s Disease, and Vascular Dementia

“…Currently, the differential diagnosis of dementia is largely based on the symptom spectrum of patients. Recent progress in molecular imaging (Janelidze et al, 2020 ; Kantarci et al, 2020 ; Kozlova et al, 2020 ) and cerebrospinal fluid (CSF) biomarkers (Altomare et al, 2019 ; Llibre-Guerra et al, 2019 ) improved the diagnostic accuracy of dementia. However, due to the high cost and invasiveness of these diagnostic strategies, blood-based biomarkers are in urgent need for the diagnosis and differential diagnosis of dementia.…”